Michelle Luo

720 total citations
32 papers, 223 citations indexed

About

Michelle Luo is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Michelle Luo has authored 32 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 15 papers in Epidemiology and 12 papers in Immunology. Recurrent topics in Michelle Luo's work include Inflammatory Bowel Disease (19 papers), Microscopic Colitis (15 papers) and Biosimilars and Bioanalytical Methods (11 papers). Michelle Luo is often cited by papers focused on Inflammatory Bowel Disease (19 papers), Microscopic Colitis (15 papers) and Biosimilars and Bioanalytical Methods (11 papers). Michelle Luo collaborates with scholars based in United States, Canada and Greece. Michelle Luo's co-authors include Trevor Lissoos, Nabeel Khan, Bryan M. Johnstone, Jeffrey S. McCombs, Lizheng Shi, James D. Lewis, Frank I. Scott, Brian E. Lacy, Annie Guérin and Rajeev Ayyagari and has published in prestigious journals such as Blood, PLoS ONE and The American Journal of Gastroenterology.

In The Last Decade

Michelle Luo

29 papers receiving 222 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Luo United States 8 131 109 52 39 34 32 223
Lauren Beswick Australia 10 174 1.3× 172 1.6× 40 0.8× 64 1.6× 13 0.4× 26 306
Rachel Tayler United Kingdom 7 159 1.2× 89 0.8× 56 1.1× 70 1.8× 8 0.2× 20 283
David Choi United States 10 142 1.1× 107 1.0× 44 0.8× 52 1.3× 11 0.3× 43 237
Sheldon Lidofsky United States 5 142 1.1× 119 1.1× 26 0.5× 47 1.2× 11 0.3× 11 227
Karen Frost Canada 7 212 1.6× 162 1.5× 91 1.8× 91 2.3× 17 0.5× 21 361
I.A. Mouzas Greece 4 250 1.9× 220 2.0× 23 0.4× 93 2.4× 39 1.1× 7 305
Joanna Sieczkowska Poland 7 113 0.9× 77 0.7× 147 2.8× 80 2.1× 37 1.1× 13 281
Jonathan Blackwell United Kingdom 10 245 1.9× 181 1.7× 28 0.5× 112 2.9× 15 0.4× 23 348
Joshua D. Noe United States 13 308 2.4× 220 2.0× 118 2.3× 84 2.2× 7 0.2× 35 539

Countries citing papers authored by Michelle Luo

Since Specialization
Citations

This map shows the geographic impact of Michelle Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Luo more than expected).

Fields of papers citing papers by Michelle Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Luo. The network helps show where Michelle Luo may publish in the future.

Co-authorship network of co-authors of Michelle Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Luo. A scholar is included among the top collaborators of Michelle Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Luo. Michelle Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Michelle, et al.. (2025). Discussion of the correlation between HIV-1 gp120-induced intestinal dysbiosis and intestinal barrier loss. International Journal of Infectious Diseases. 152. 107558–107558. 1 indexed citations
2.
3.
Byrnes, James R., Robert A. Campbell, Lori A. Holle, et al.. (2023). Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration. Blood. 143(5). 444–455. 5 indexed citations
4.
Yang, Yi, Ananya Dutta, Michelle Luo, et al.. (2023). Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression. Molecular Oncology. 18(1). 113–135. 3 indexed citations
5.
Herndon, Thomas M., Cristina Ausín, Sarah J. Schrieber, et al.. (2023). Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis. PLoS ONE. 18(10). e0292231–e0292231. 25 indexed citations
6.
Mantzaris, Gerassimos J., Brian Bressler, Shashi Adsul, et al.. (2023). Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study. European Journal of Gastroenterology & Hepatology. 36(3). 281–291. 4 indexed citations
7.
Mantzaris, Gerassimos J., Andrés Yarur, Shu Wang, et al.. (2021). DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data. Journal of Crohn s and Colitis. 15(Supplement_1). S095–S096. 2 indexed citations
8.
9.
Bressler, Brian, Andrés Yarur, Uri Kopylov, et al.. (2020). P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study. Journal of Crohn s and Colitis. 14(Supplement_1). S381–S382. 1 indexed citations
10.
Scott, Frank I., Michelle Luo, Yash Shah, et al.. (2019). Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. Journal of Crohn s and Colitis. 14(5). 575–587. 6 indexed citations
11.
Khan, Nabeel, et al.. (2019). Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis. Inflammatory Bowel Diseases. 26(3). 462–468. 43 indexed citations
12.
Lacy, Brian E., et al.. (2019). Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therapeutic Advances in Gastroenterology. 12. 3972007190–3972007190. 15 indexed citations
13.
Chang, Helena, et al.. (2018). P525 Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre. Journal of Crohn s and Colitis. 12(supplement_1). S371–S372. 2 indexed citations
14.
Shmidt, Eugenia, Adam C. Winters, Khadija Chaudrey, et al.. (2017). P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium. Inflammatory Bowel Diseases. 23. 2 indexed citations
15.
Khan, Nabeel, et al.. (2017). Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Drugs & Aging. 34(11). 859–868. 36 indexed citations
16.
Khalid, Javaria Mona, et al.. (2016). Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohnʼs Disease Treated with Vedolizumab vs. Infliximab in the United States. The American Journal of Gastroenterology. 111. S316–S317. 1 indexed citations
17.
Epstein, J., et al.. (2011). Benefits associated with a broad selection of dosage strengths for recombinant factor VIII products. Haemophilia. 18(2). 182–186. 1 indexed citations
18.
Sprinz, Eduardo, Stephen Green, Michelle Luo, et al.. (2006). Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy. HIV Clinical Trials. 7(6). 291–308. 2 indexed citations
19.
Heijde, D. van der, et al.. (2005). Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.. Oxford University Research Archive (ORA) (University of Oxford). 52(9). 4 indexed citations
20.
McCombs, Jeffrey S., Michelle Luo, Bryan M. Johnstone, & Lizheng Shi. (2000). The Use of Conventional Antipsychotic Medications for Patients with Schizophrenia in a Medicaid Population: Therapeutic and Cost Outcomes over 2 Years. Value in Health. 3(3). 222–231. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lauren Beswick Breakdown of academic impact, for papers by Rachel Tayler Breakdown of academic impact, for papers by David Choi Breakdown of academic impact, for papers by Sheldon Lidofsky Breakdown of academic impact, for papers by Karen Frost Breakdown of academic impact, for papers by I.A. Mouzas Breakdown of academic impact, for papers by Joanna Sieczkowska Breakdown of academic impact, for papers by Jonathan Blackwell Breakdown of academic impact, for papers by Joshua D. Noe
Rankless by CCL
2026